Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Norgine","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","amount":"$290.0 million","upfrontCash":"$30.0 million","newsHeadline":"AMAG Pharmaceuticals and Norgine B.V. Ink Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II"},{"orgOrder":0,"company":"Norgine","sponsor":"US WorldMeds","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine Enter Agreement to Commercialise DFMO in Independent States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Norgine","sponsor":"Covis Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data in The European Heart Journal Show Ciraparantag Reverses the Anticoagulant Activity of Apixaban and Rivaroxaban in Elderly Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II"},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine Announces Closing of Investment from Goldman Sachs Asset Management","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Norgine","sponsor":"Fennec Pharmaceuticals","pharmaFlowCategory":"D","amount":"$271.6 million","upfrontCash":"$43.4 million","newsHeadline":"Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Approved","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved"},{"orgOrder":0,"company":"Norgine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Norgine Receives Positive ChMP Opinion Recommending Approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the Treatment of Malignant Hyperthermia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Norgine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Norgine B.V. Submits Marketing Authorisation Application via Project Orbis for Eflornithine (difluoromethylornithine [DFMO]) in High-risk Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"NETHERLANDS","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Norgine

    Menu

    Norgine

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Norgine

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Norgine B.V. Submits Marketing Authorisation Application via Project Orbis for Eflornithine (difluoromethylornithine [DFMO]) in High-risk Neuroblastoma

              Details:

              Iwilfin (eflornithine) is a USFDA approved ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma.

              Lead Product(s): Eflornithine

              Therapeutic Area: Oncology Product Name: Iwilfin

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 15, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Norgine

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Norgine Receives Positive ChMP Opinion Recommending Approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the Treatment of Malignant Hyperthermia

              Details:

              NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.

              Lead Product(s): Dantrolene

              Therapeutic Area: Musculoskeletal Product Name: NPJ5008

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Norgine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

              Details:

              Norgine will commercialize Pedmarqsi (sodium thiosulfate) in Europe, Australia and New Zealand. Pedmarqsi is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity induced by cisplatin chemotherapy in patients with localized, non-metastatic solid tumors.

              Lead Product(s): Sodium Thiosulfate

              Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Pedmarqsi

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Fennec Pharmaceuticals

              Deal Size: $271.6 million Upfront Cash: $43.4 million

              Deal Type: Licensing Agreement March 18, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Norgine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Norgine Announces Closing of Investment from Goldman Sachs Asset Management

              Details:

              The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.

              Lead Product(s): Sodium Chloride,Sodium Bicarbonate,Potassium Chloride

              Therapeutic Area: Gastroenterology Product Name: Movicol

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Goldman Sachs Asset Management

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing December 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Norgine

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Data in The European Heart Journal Show Ciraparantag Reverses the Anticoagulant Activity of Apixaban and Rivaroxaban in Elderly Patients

              Details:

              Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).

              Lead Product(s): Ciraparantag

              Therapeutic Area: Hematology Product Name: PER977

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Covis Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Norgine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Norgine Enter Agreement to Commercialise DFMO in Independent States

              Details:

              DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy.

              Lead Product(s): Eflornithine

              Therapeutic Area: Oncology Product Name: DFMO

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: US WorldMeds

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Norgine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AMAG Pharmaceuticals and Norgine B.V. Ink Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand

              Details:

              Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontrolled bleeding.

              Lead Product(s): Ciraparantag

              Therapeutic Area: Hematology Product Name: PER977

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: AMAG Pharmaceuticals

              Deal Size: $290.0 million Upfront Cash: $30.0 million

              Deal Type: Licensing Agreement July 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Norgine

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU

              Details:

              Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.

              Lead Product(s): Potassium Chloride,Sodium Chloride,Ascorbic Acid

              Therapeutic Area: Gastroenterology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Faes Farma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY